| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 23, 2004
Accepted on October 14, 2004
,25-Dihydroxyvitamin D3 and 25-Hydroxyvitamin D3 in the Blood and Tissues of the 25-Hydroxyvitamin D-24-Hydroxylase (Cyp24a1) Null Mouse*
Department of Biochemistry (S.M., V.B, G.J.) Queen's University, Kingston (Ontario) Canada K7L 3N6; Genetics Unit (A.A., R.St-A.), Shriners Hospital for Children, Montreal (Quebec) Canada H3G 1A6; Departments of Medicine, Surgery, and Human Genetics (R.St-A.), McGill University, Montreal (Quebec) Canada H3A 2T5; and Endocrine Unit (Y.S., M.B.D.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
* To whom correspondence should be addressed. E-mail: gj1{at}post.queensu.ca.
The 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) plays an important role in regulating concentrations of both the precursor 25-hydroxyvitamin D3 [25(OH)D3], and the hormone 1
,25-dihydroxyvitamin D3 [1
,25(OH)2D3]. Previous studies suggest that Cyp24a1 null mice cannot clear exogenous 1
,25(OH)2D3 efficiently. Here, we examined the metabolic clearance in Cyp24a1 null mice in vivo and in vitro using a physiological dose of [1
-3H]1
,25(OH)2D3 or [26,27-methyl-3H]25(OH)D3. Cyp24a1 null mice showed difficulty in eliminating [1
-3H]1
,25(OH)2D3 from the bloodstream and tissues over a 96 h time course whereas heterozygotic mice eliminated the hormone within 6-12 h, though there was clearance of labeled hormone into water-soluble products involving liver in both genotypes. RT-PCR showed that Cyp24a1 null mice have decreased expression of 25-hydroxyvitamin D-1
-hydroxylase that must play a role in their survival. Following the administration of [26,27-methyl-3H]25(OH)D3, Cyp24a1 null mice showed higher [26,27-methyl-3H]25(OH)D3 levels and no [26,27-methyl-3H]24,25(OH)2D3 formation, while heterozygotic mice showed significant [26,27-methyl-3H]24,25(OH)2D3 production. Based upon in vitro experiments, keratinocytes from Cyp24a1 null mice fail to synthesize [1
-3H]calcitroic acid from [1
-3H]1
,25(OH)2D3 or [26,27-methyl-3H]24,25(OH)2D3 from [26,27-methyl-3H]25(OH)D3 as do control mice, confirming the target cell catabolic role of CYP24A1 in these processes. Finally, the role of vitamin D receptor (VDR) in the vitamin D catabolic cascade was examined using VDR null mice. Keratinocytes from VDR null mice failed to metabolize [1
-3H]1
,25(OH)2D3 confirming the importance of vitamin D-inducible, VDR-mediated C24-oxidation pathway in target cells. These results suggest that the absence of CYP24A1 or VDR retards catabolism of 1
,25(OH)2D3 and 25(OH)D3 reinforcing the physiological importance of CYP24A1 in vitamin D homeostasis.
25-Dihydroxyvitamin D
Vitamin D receptor
This article has been cited by other articles:
![]() |
J. Tan, P. P. Dwivedi, P. Anderson, B. K. Nutchey, P. O'Loughlin, H. A. Morris, B. K. May, A. Ferrante, and C. S. Hii Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity Mol. Cancer Ther., December 1, 2007; 6(12): 3131 - 3138. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Prosser, M. Kaufmann, B. O'Leary, V. Byford, and G. Jones Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1{alpha},25-(OH)2D3-26,23-lactone PNAS, July 31, 2007; 104(31): 12673 - 12678. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Masuda and G. Jones Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |